# A PK Study of IkT-148009 in Older and Elderly Healthy Subjects

> **NCT06644326** · PHASE1 · COMPLETED · sponsor: **ABLi Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 100mg IkT-148009 Wet
- **DRUG:** 200 mg Itraconazole
- **DRUG:** 100mg IkT-148009 Dry
- **DRUG:** 50mg IkT-148009 Wet

## Key facts

- **NCT ID:** NCT06644326
- **Lead sponsor:** ABLi Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-21
- **Primary completion:** 2024-08-17
- **Final completion:** 2024-08-27
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644326, "A PK Study of IkT-148009 in Older and Elderly Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06644326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*